Table 1.
Demographic and clinical characteristics of all patients
| Baseline characteristics | n = 129 |
|---|---|
| Age, years | 62.5 (16) |
| Follow-up time, years | 7.2 (5.4) |
| Gender | |
| Male | 51 (40) |
| Female | 78 (60) |
| Race | |
| Caucasian | 102 (79) |
| African American | 13 (10) |
| Hispanic | 7 (5) |
| Asian | 5 (4) |
| Others | 2 (1) |
| ANCA type | |
| PR3 | 68 (53) |
| MPO | 56 (43) |
| PR3 + MPO | 2 (1.5) |
| Negative | 2 (1.5) |
| Unknown | 1 (1) |
| Disease type | |
| GPA | 76 (59) |
| MPA | 48 (37) |
| eGPA | 5 (4) |
| Prior induction treatment | |
| Rituximab | 124 (96) |
| Cyclophosphamide | 50 (39) |
| Methotrexate | 14 (11) |
| Plasma exchange | 4 (3) |
| Leflunomide | 3 (2) |
| Cyclosporine | 1 (1) |
| Infliximab | 1 (1) |
| Azathioprine | 2 (2) |
| Adalimumab | 1 (1) |
| Etanercept | 1 (1) |
| PJP prophylaxis | |
| Yes | 57 (44) |
| No | 72 (56) |
| Chemoprophylaxis | |
| Trimethoprim-sulfamethoxazole | 40 (70) |
| Dapsone | 9 (16) |
| Atovaquone | 8 (14) |
PR3, proteinase-3; MPO, myeloperoxidase; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; eGPA, eosinophilic granulomatosis with polyangiitis, ANCA, anti-neutrophil cytoplasmic antibody; PJP, Pneumocystis jirovecii pneumonia.
Numeric continuous values are presented as mean (±SD) and categorical variables as n (%).